Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer | MRK Stock NewsStockTitan·1 day ago, 04:00 AMREGN+0.11%
Revolution Medicines says FDA accepts daraxonrasib NDA for previously treated metastatic pancreatic cancerPUBT·1 day ago, 03:11 PMRVMD+3.13%
Regeneron Pharmaceuticals, Inc. (REGN) Faces Securities Class Action Amid Disclosures About Key Trial's Protocol and Ultimate Failure - HBSSPR Newswire·2 days ago, 06:00 PMREGN+0.11%
16:26 ETERAS INVESTOR DEADLINE: Erasca, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - HBSSprnewswire·2 days ago, 03:28 PMERAS-0.87%RVMD+3.13%
Regulatory Momentum for Daraxonrasib and RAS Pipeline Upside Support Charles Zhu’s Buy Rating on RVMD with Unchanged $263 Price TargetTip Ranks·1 day ago, 04:35 PMRVMD+3.13%
REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA LawMorningStar·2 days ago, 03:14 PMREGN+0.11%
Gilead, Merck Advance Potential Blockbuster Weekly HIV Pillbenzinga_article·2 days ago, 12:28 PMMRK+2.36%GIS
Gilead posts press release on once-weekly oral HIV regimen trial resultsPUBT·2 days ago, 09:01 AMGILD+0.40%GIS
Merck Just Won The Race For The First Cholesterol Pill: What It Means For Your Heart And Your Portfoliobenzinga_article·Jul 20 at 04:11 PMMRK+2.36%AMGN+1.49%
GSK notifies availability of ViiV Healthcare AIDS 2026 data presentation announcementPUBT·Jul 21 at 03:01 AMGSK-4.00%GSK
Florida Financial Advisors LLC Decreases Stock Holdings in Gilead Sciences, Inc. $GILDMarket Beat·2 days ago, 04:20 AMGILD+0.40%GIS
Vertex Pharmaceuticals (VRTX) Stock Trades Below Fair Value After Deal PlansSimplywall·Jul 20 at 08:14 PMVRTX+0.11%CRNX-8.00%
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,000.00Market Beat·2 days ago, 09:18 AMREGN+0.11%
Amgen Inc. Stock Outperforms Competitors On Strong Trading DayMarketWatch Automated·12 hours agoAMGN+1.49%
